CooperVision’s MiSight® 1 day contact lens is in the national spotlight for receiving prestigious recognition from Popular Science and Contact Lens Spectrum.
In December, MiSight® 1 day garnered the 2020 Popular Science “Best of What’s New Award” in the health category. The award recognizes up to 100 of the most innovative technologies from the past year across 10 categories, such as health, home, aerospace and security. MiSight® 1 day is one of nine health category winners including a COVID-19 rapid antigen test, a telehealth diagnostics kit, and other technologies that are taking on today’s health challenges. Beyond health, MiSight® 1 day stands alongside innovations from Amazon, Google and NASA.
The accolades continued into 2021 when Contact Lens Spectrum named MiSight® 1 day as its inaugural Product of the Year based on input solicited from its readership. MiSight® 1 day was received for being the first FDA-approved* soft contact lens designed for myopia control proven to slow myopia progression in children, aged 8-12 at the initiation of treatment†1—a remarkable accomplishment.
“Two out of every five Americans have myopia,[i] a disease that both impairs distance vision and increases the risk of sight-threatening conditions later in life,”[ii] explained Jerry Warner, Executive Vice President, Americas and Global Commercial Functions for CooperVision. “The introduction of MiSight® 1 day contact lenses in the U.S. has meant that age-appropriate children, for the first time, have access to an FDA-approved* solution that can help them reduce the severity of myopia progression and enjoy more brilliant futures. We are honored that Popular Science and Contact Lens Spectrum have recognized the impact of this technology.”
This recognition comes as CooperVision celebrates the 1-year anniversary of MiSight® 1 day’s groundbreaking FDA approval* and the more than 2,000 U.S. eye care professionals (ECPs) who are now certified and able to prescribe its Brilliant Futures™ Myopia Management Program with the MiSight® 1 day lens. The accolades will likely drive even more parents to seek information about participating Brilliant Futures™ ECPs—furthering the position of myopia control in mainstream conversation and driving action to address the growing myopia epidemic.
*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters(spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
†Compared to a single vision 1 day lens over a 3-year period.
1Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-67.
[i] Vitale S, Sperduto RD, Ferris FL 3rd. Increased prevalence of myopia in the United States between 1971-1972 and 1999-2004. Arch Ophthalmol. 2009;127(12):1632-1639. doi:10.1001/archophthalmol.2009.303
[ii] Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012;31:622-60.
